According to a new report, published by KBV research, The Global Minimal Residual Disease Testing Market size is expected to reach $2.7 billion by 2028, rising at a market growth of 14.2% CAGR during the forecast period.
The Leukemia segment is showcasing a CAGR of 14.5% during (2022 - 2028). The presence of leukemia can be analyzed by using various MRD testing methods like PCR, NGS, and flow cytometry. In the detection of acute lymphoblastic leukemia (ALL), MRD has even become a standard diagnosing technique among adult and pediatric ALL patients. The tests also help in diagnosing those patients in which chances for relapse are higher and hence facilitate early or additional treatments.
The Hospitals & Specialty Clinics segment is generating highest revenue share in the Global Minimal Residual Disease Testing Market by End User in 2021 thereby, achieving a market value of $1.3 billion by 2028. MRD testing is mostly done in hospitals and specialty clinics, especially cancer-treating hospitals. Various governmental and non-governmental portals also publish the list of hospitals and specialty clinics by specific cancer type for easy access to information for the general public.
The Next-Generation Sequencing (NGS) segment has shown the growth rate of 14.4% during (2022 - 2028). The next-generation sequencing (NGS) segment procured a considerable growth rate in the minimal residual disease testing market in 2021. Theoretically, NGS for MRD diagnosis can be conducted for all leukemia-specific genetic anomalies. It is expected that this approach can become applicable to more patients with improved bioinformatics and experimental approaches.
The North America market dominated the Global Minimal Residual Disease Testing Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $1 billion by 2028.The Europe market is experiencing a CAGR of 14% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 15.3% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/minimal-residual-disease-testing-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Bio-Rad Laboratories, Inc., Guardant Health, Inc., Invitae Corporation (ArcherDX, Inc.), Bio-Techne Corporation, F. Hoffmann-La Roche Ltd., ICON plc (MolecularMD Corporation), Natera, Inc., Sysmex Corporation, Laboratory Corporation of America Holdings, and Invivoscribe, Inc.
By Application
By End User
By Technology
By Geography
Companies Profiled
Unique Offerings 
